Online citations, reference lists, and bibliographies.
← Back to Search

Value Of PAX8, PAX2, Claudin-4, And H-caldesmon Immunostaining In Distinguishing Peritoneal Epithelioid Mesotheliomas From Serous Carcinomas

N. Ordóñez
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Distinguishing between peritoneal epithelioid mesotheliomas and papillary serous carcinomas involving the peritoneum can be difficult on routine histological preparations, but this differential diagnosis can be facilitated by the use of immunohistochemistry. Recent investigations have indicated that PAX8, PAX2, claudin-4, and h-caldesmon are immunohistochemical markers that can assist in distinguishing between these two malignancies; however, much of the information published on the value of these markers is either insufficient or contradictory. The purpose of this study is to resolve some of the existing controversies and to fully determine the practical value of these markers for assisting in the differential diagnosis between peritoneal mesotheliomas and serous carcinomas. In order to do so, a total of 40 peritoneal epithelioid mesotheliomas and 45 serous carcinomas (15 primary, 30 metastatic to the peritoneum) were investigated. PAX8 and PAX2 nuclear positivity was demonstrated in 42 (93%) and 25 (56%) of the serous carcinomas, respectively, whereas none of the mesotheliomas expressed either marker. Forty-four (98%) of the serous carcinomas exhibited claudin-4 reactivity along the cell membrane, whereas none of the mesotheliomas were positive for this marker. All of the serous carcinomas and mesotheliomas were negative for h-caldesmon. Based on these results, it is concluded that PAX8 and claudin-4 have a higher sensitivity and specificity for assisting in discriminating between peritoneal epithelioid mesotheliomas and serous carcinomas when compared with all of the other positive carcinoma markers that are, at present, recommended to be included in the immunohistochemical panels used in this differential diagnosis. Even though it is highly specific, PAX2 has little practical value in the diagnosis of peritoneal epithelioid mesotheliomas as its sensitivity is low. The h-caldesmon is not useful.
This paper references
10.1097/PAI.0b013e3181d712ef
PAX-2 Expression in Non-neoplastic, Primary Neoplastic, and Metastatic Neoplastic Tissue: A Comprehensive Immunohistochemical Study
Q. J. Zhai (2010)
10.1016/0092-8674(92)90281-G
Pax in development
P. Gruss (1992)
10.1016/J.YGYNO.2006.08.052
Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.
N. Bowen (2007)
10.1309/AJCPU0FION3RKKFO
Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
L. Zhao (2012)
10.1097/PAS.0b013e318033e7a8
h-Caldesmon, Calretinin, Estrogen Receptor, and Ber-EP4: A Useful Combination of Immunohistochemical Markers for Differentiating Epithelioid Peritoneal Mesothelioma From Serous Papillary Carcinoma of the Ovary
C. Comin (2007)
10.1309/8FCHQ3VPBWM7B5X9
Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful.
R. Barnetson (2006)
10.1002/dc.21442
Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions
W. Wiseman (2011)
10.1385/CBB:35:3:275
Caldesmon and smooth-muscle regulation
C. Wang (2007)
10.1002/dc.21380
Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions
S. Lonardi (2011)
10.1097/PAI.0b013e3182366531
Is PAX2 a Reliable Marker in Differentiating Diffuse Malignant Mesotheliomas of Peritoneum From Serous Carcinomas of Müllerian Origin?
F. Gao (2012)
10.1016/J.HUMPATH.2006.08.010
What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.
N. Ordóñez (2007)
10.1097/PAS.0b013e31822d787c
PAX2 and PAX8 Expression in Primary and Metastatic Müllerian Epithelial Tumors: A Comprehensive Comparison
A. Ozcan (2011)
10.1097/PAI.0b013e3181e78ff8
The Utility of Pax-2 and Renal Cell Carcinoma Marker Immunohistochemistry in Distinguishing Papillary Renal Cell Carcinoma From Nonrenal Cell Neoplasms With Papillary Features
S. Sharma (2010)
10.1002/BIES.950190905
Pax genes and organogenesis
E. Dahl (1997)
10.1016/J.BCP.2006.06.024
PAX genes: roles in development, pathophysiology, and cancer.
D. Lang (2007)
10.1523/JNEUROSCI.14-03-01395.1994
Roles of Pax-genes in developing and adult brain as suggested by expression patterns
A. Stoykova (1994)
10.1152/AJPCELL.00558.2003
The tight junction: a multifunctional complex.
E. Schneeberger (2004)
10.1097/00000478-200604000-00006
h-Caldesmon, a Useful Positive Marker in the Diagnosis of Pleural Malignant Mesothelioma, Epithelioid Type
C. Comin (2006)
10.1016/S0079-6107(02)00037-8
Tight junction proteins.
L. González-Mariscal (2003)
10.1097/00000478-199810000-00005
Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
N. Ordóñez (1998)
malignant mesothelioma, epithelioid type
AN Husain (2012)
10.1046/j.1365-2559.2002.01352.x
Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum
R. Attanoos (2002)
10.1016/0046-8177(90)90050-F
A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
N. Khoury (1990)
10.14670/HH-22.1185
Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Y. Choi (2007)
10.1136/jcp.2005.028589
Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura
Y. Soini (2006)
10.1016/j.humpath.2012.05.014
Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.
N. Ordóñez (2013)
Developmental changes in expression of contractile and cytoskeletal proteins in human aortic smooth muscle.
M. Glukhova (1990)
Caldesmon, a novel regulatory protein in smooth muscle and nonmuscle actomyosin systems.
K. Sobue (1991)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
Immunohistochemical diagnosis of epithelioid mesotheliomas: A critical review of old markers, new markers
Nelson G. Ord ez (2002)
10.5858/arpa.2012-0214-OA
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
10.1007/s00709-004-0057-3
Nonmuscle caldesmon: its distribution and involvement in various cellular processes
R. Dąbrowska (2004)
10.1097/00000478-198908000-00004
Peritoneal Malignant Mesothelioma versus Serous Papillary Adenocarcinoma: A Histochemical and Immunohistochemical Comparison
D. Bollinger (1989)
10.1016/J.HUMPATH.2005.08.008
Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
N. Ordóñez (2005)
10.1038/modpathol.3800827
Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?
G. Tong (2007)
10.1387/IJDB.10535325
Pax2 in development and renal disease.
G. Dressler (1999)
10.1038/modpathol.3800549
Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas
C. Lódi (2006)
Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
H. Yoshida (2011)
10.1007/s00428-007-0448-x
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions
F. Facchetti (2007)
10.1097/PAS.0b013e318176dba7
The Utility of PAX-2 in Distinguishing Metastatic Clear Cell Renal Cell Carcinoma From its Morphologic Mimics: An Immunohistochemical Study With Comparison to Renal Cell Carcinoma Marker
N. Gokden (2008)
10.1097/00004347-200201000-00003
A Panel of Immunohistochemical Stains, Including Carcinoembryonic Antigen, Vimentin, and Estrogen Receptor, Aids the Distinction Between Primary Endometrial and Endocervical Adenocarcinomas
W. G. McCluggage (2002)
10.1073/PNAS.84.24.9049
Expression of high and low molecular weight caldesmons during phenotypic modulation of smooth muscle cells.
N. Ueki (1987)
10.1097/PAI.0b013e3182025f66
Expression of PAX8 in Normal and Neoplastic Tissues: A Comprehensive Immunohistochemical Study
D. Tacha (2011)
10.1097/PAP.0b013e318253465d
Value of PAX 8 Immunostaining in Tumor Diagnosis: A Review and Update
N. Ordóñez (2012)
10.1309/AJCPHSUJ15NEYMIP
A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
Y. Takeshima (2008)
10.1146/ANNUREV.PHYSIOL.60.1.161
Role of tight junctions in establishing and maintaining cell polarity.
M. Cereijido (1998)
10.1016/S0955-0674(96)80087-1
Pax genes and their roles in cell differentiation and development.
A. Mansouri (1996)
10.1097/PAS.0b013e3181da7687
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Anna R. Laury (2010)
10.1097/PAP.0b013e318271a382
Value of PAX2 Immunostaining in Tumor Diagnosis: A Review and Update
N. Ordóñez (2012)
10.1097/PGP.0b013e3181a76fa2
PAX 2: A Novel Müllerian Marker for Serous Papillary Carcinomas to Differentiate From Micropapillary Breast Carcinoma
M. Chivukula (2009)
10.1002/1097-0142(197909)44:3<937::AID-CNCR2820440322>3.0.CO;2-K
Absence of carcinoembryonic antigen‐like material in mesothelioma An immunohistochemical differentiation from other lung cancers
N. Wang (1979)
10.1038/modpathol.2011.3
PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study
A. Ozcan (2011)
10.1097/PAS.0b013e31816d71ad
Expression of Pax8 as a Useful Marker in Distinguishing Ovarian Carcinomas From Mammary Carcinomas
D. Nonaka (2008)
Pax-2 controls multiple steps of urogenital development.
M. Torres (1995)
10.1210/EN.2006-1054
Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy.
J. Mittag (2007)
10.1097/PAS.0b013e3181962dcd
Immunohistochemical Panel to Identify the Primary Site of Invasive Micropapillary Carcinoma
T. Lotan (2009)
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.
C. L. Collins (1992)
10.1093/AJCP/94.1.18
Expression of "myelomonocytic" antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces.
M. Wick (1990)
10.1038/modpathol.3800471
The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study
N. Ordóñez (2006)
10.1371/journal.pmed.0050232
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
M. Köbel (2008)
10.1038/modpathol.3800259
Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma
Albert Y Chu (2005)
10.1002/dc.21426
Pax8: A marker for carcinoma of Müllerian origin in serous effusions
G. Tong (2011)
10.1309/QLV6-HH0H-UCTF-WEF6
WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
B. H. Lee (2002)
10.1038/modpathol.2008.108
Immunophenotyping of serous carcinoma of the female genital tract
S. Nofech-Mozes (2008)



This paper is referenced by
10.1002/cncy.21392
Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
V. Jo (2014)
10.1097/PGP.0000000000000146
Selected Topics in Peritoneal Pathology
P. Baker (2014)
Immunohistochemical panel of glypican-3, hepatocyte paraffin antigen-1, arginase-1, cytokeratin-19, and human epithelial membrane antigen for the differential diagnosis of liver tumors
Kan Jiang (2019)
10.20524/aog.2018.0305
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives
S. Boussios (2018)
10.1097/PAP.0000000000000069
Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry
J. Conner (2015)
10.1097/PAI.0b013e31828a83c5
Value of Podoplanin as an Immunohistochemical Marker in Tumor Diagnosis: A Review and Update
N. Ordóñez (2014)
10.21037/tlcr.2019.11.29
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
10.1136/jclinpath-2017-204787
Diagnostic immunohistochemistry in gynaecological neoplasia: a brief survey of the most common scenarios
E. Kuhn (2017)
10.3389/fonc.2020.01742
The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
Eric Rozitis (2020)
10.1097/PAI.0b013e31829b6fbd
Value of Calretinin Immunostaining in Diagnostic Pathology: A Review and Update
N. Ordóñez (2014)
10.1007/978-3-319-96681-6
Oncological Surgical Pathology
C. Moran (2020)
10.5858/arpa.2017-0537-RA
The Diagnosis of Pleural Tumors Other Than Mesothelioma.
R. Attanoos (2018)
10.1016/j.yexcr.2018.08.024
Cytotoxicity of Clostridium perfringens enterotoxin depends on the conditions of claudin‐4 in ovarian carcinoma cells
S. Tanaka (2018)
10.1016/j.prp.2015.04.001
Low-grade serous primary peritoneal carcinoma incidentally found in a hernia sac.
J. Val-Bernal (2015)
10.1097/PAS.0000000000000935
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma
D. Chapel (2017)
10.4103/IJPM.IJPM_832_19
Role of immunohistochemistry in gynec oncopathology including specific diagnostic scenarios with associated treatment implications
B. Rekhi (2020)
10.1016/j.ctrv.2015.05.001
The established and future biomarkers of malignant pleural mesothelioma.
V. Panou (2015)
10.1097/PAI.0000000000000549
Does Strong and Diffuse PAX-8 Positivity Occur in Primary Lung Carcinoma? An Immunohistochemical Study of 418 Cases and Review of the Literature
K. McHugh (2019)
10.1186/s12957-017-1134-3
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review
J. Yuan (2017)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.1016/j.humpath.2014.03.006
Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
N. Ordóñez (2014)
10.1007/978-1-4471-2825-0_16
Malignant Mesothelioma: Pathology
S. Anttila (2014)
10.1159/000447008
Diagnostic Usefulness of Claudin-3 and Claudin-4 for Immunocytochemical Differentiation between Metastatic Adenocarcinoma Cells and Reactive Mesothelial Cells in Effusion Cell Blocks
N. I. Kim (2016)
10.1016/j.humpath.2012.11.016
Broad-spectrum immunohistochemical epithelial markers: a review.
N. Ordóñez (2013)
10.1097/PAP.0000000000000098
The Origin of Epithelial Neoplasms of the Ovary: An Alternative View
E. Silva (2016)
10.5858/arpa.2014-0057-RA
The utility of immunohistochemistry in the differential diagnosis of gynecologic disorders.
H. Kaspar (2015)
10.1053/j.semdp.2014.03.006
Use of immunohistochemistry in the diagnosis of miscellaneous and metastatic tumors of the uterine corpus and cervix.
E. Euscher (2014)
10.1111/his.13970
Endometriosis‐related pathology: a discussion of selected uncommon benign, premalignant and malignant lesions
W. G. McCluggage (2020)
10.1007/978-981-10-7053-2_16
Rare Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
A. Bhatt (2018)
10.1016/j.annpat.2015.06.006
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
P. Dartigues (2015)
10.1097/PAP.0000000000000256
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin
A. Bellizzi (2020)
10.1016/j.humpath.2016.08.005
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
B. Davidson (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar